<DOC>
	<DOCNO>NCT01846442</DOCNO>
	<brief_summary>The purpose study determine dose-response vaginal mucosa parameter local action DHEA postmenopausal woman suffer vaginal atrophy .</brief_summary>
	<brief_title>Topical DHEA Against Vaginal Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Postmenopausal woman ( non hysterectomized hysterectomized ) Women 40 75 year age Willing participate study sign inform consent Women low maturation index ( great part guidance 5 % superficial cell vaginal smear ) Women vaginal pH 5 Women selfidentified least one moderate severe symptom vulvovaginal atrophy Undiagnosed abnormal genital bleed Hypertension equal 160/95 mm Hg control standard therapy The administration investigational drug within 30 day screen visit Endometrial hyperplasia biopsy perform screen endometrial cancer Use estrogens/progestins product ( vaginal , oral , pellet , transdermal , etc ) 4 week 6 month ( depend product use ) prior study entry</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Vulvar/vaginal atrophy</keyword>
	<keyword>Atrophic Vaginitis</keyword>
	<keyword>Dehydroepiandrosterone</keyword>
	<keyword>DHEA</keyword>
	<keyword>Prasterone</keyword>
	<keyword>Vaginorm</keyword>
	<keyword>Menopause</keyword>
</DOC>